NCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
Clinical Trials
7 trialsNCT06435312 2026-03-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT06540144 2026-02-27
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT05303532 2026-02-23
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT06281964 2025-12-16
KANNON-2
Avistone Biotechnology Co., Ltd.
Phase 3 Enrolling by invitation
NCT06759857 2025-01-06
FHND9041
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 3 Enrolling by invitation